HCP
IRWD icon

Hexagon Capital Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

Hexagon Capital Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-199
Closed -$1.95K – 1438
2023
Q2 		$2.12K Buy
199
+59
+42% +$634 ﹤0.01% 1071
2023
Q1 		$1.47K Buy
140
+104
+289% +$1.17K ﹤0.01% 1121
2022
Q4 		$446 Hold
36
– – ﹤0.01% 1305
2022
Q3 		$0 Buy
+36
New +$408 ﹤0.01% 1369

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Hexagon Capital Partners's IRWD Position: Q3 2023 in Review

Hexagon Capital Partners sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2023, closing a stake of 199 shares — an estimated $1.95K sold.

Hexagon Capital Partners first reported a position in IRWD in Q3 2022 and held it in 4 quarters. The position peaked at $2.12K in Q2 2023. 248 funds tracked by Wall St. Rank hold IRWD as of Q3 2023.

  • Hexagon Capital Partners reported no remaining Ironwood Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Hexagon Capital Partners sold 199 Ironwood Pharmaceuticals shares in Q3 2023, an estimated $1.95K.
  • Hexagon Capital Partners first reported a position in Ironwood Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • Hexagon Capital Partners's Ironwood Pharmaceuticals position peaked at $2.12K in Q2 2023.
  • 248 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2023.

Based on Hexagon Capital Partners's 13F filing for Q3 2023, filed 23 Oct 2023.